AstraZeneca signs deal to acquire Icosavax Inc. for $1.1 billion
LONDON, UK: AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. Under the terms of the agreement, AstraZeneca, through a subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding…